English High Court grants a dynamic website-blocking order against counterfeit medicine sellers

The English High Court has approved a "dynamic" website-blocking order in a case called Novo Nordisk v British Telecommunications & Ors, letting Novo Nordisk require UK internet providers to block websites that sell counterfeit or unlicensed versions of its semaglutide products, including Ozempic and Wegovy.^[1] The order can now expand on its own: Novo Nordisk can self-certify that a new site meets confidential criteria set by the court, and internet providers must block it without a fresh court hearing.^[1]

The case started narrower. Mr Justice Mellor first ordered providers to block four specific websites, plus any mirror or successor sites, that were selling fake or unlicensed semaglutide and other prescription-only drugs to UK consumers.^[1] When operators got around that order by launching new mirror domains, Mr Justice Adam Johnson extended it into the dynamic version, calling it a "creative form of intervention."^[1] He added that "the law is not afraid of adapting to new challenges."^[1]

What makes the ruling notable beyond speed is its scope. Website-blocking orders were built for copyright and trademark cases. Here, the court said Novo Nordisk can also flag sites for blocking based solely on criminal breaches of the UK's Human Medicines Regulations 2012, even when there's no trademark or copyright violation to point to.^[1] The UK medicines regulator, the MHRA, backed the order and told the court that counterfeit and unlicensed semaglutide products are "flooding the online market."^[1] Internet providers did not contest the order.^[1]

The order isn't unlimited. It includes a sunset clause, meaning it will expire on a set timeline, and target websites are supposed to be notified where practical and given a redacted copy of the order.^[1] Any website operator who thinks they were wrongly blocked can ask the court to vary or cancel the block as it applies to them, and can seek access to the confidential blocking criteria if they can show a legitimate interest.^[1]

Why it matters for patients

This order is a UK court ruling enforced through UK internet providers. It does not change any US law, and it does not block sites for American consumers.^[1] But it matters to US readers because it targets the same problem American patients have faced: counterfeit Ozempic and Wegovy pens reaching buyers through online sellers, often through websites that reappear under new domain names after being shut down. The UK's approach — letting a drugmaker flag and block copycat sites on an ongoing basis rather than suing each one separately — is a template other countries, including the US, could look to if regulators or companies want a faster enforcement tool.^[1] For now, the practical takeaway for US patients is unchanged: unlicensed online sellers of GLP-1 drugs remain a known source of counterfeit product, and this UK order does not reach or restrict those sellers if they operate outside the UK's jurisdiction.^[1]

What happens next

The order's self-certification process is new even in the UK, so how well it works in practice is not yet established.^[1] Law firm Osborne Clarke, which represented parties familiar with the case, said other life sciences companies are likely to seek similar orders if this one proves effective, and that the reasoning could eventually extend to other kinds of online criminal wrongdoing beyond medicines.^[1] No timeline for a broader rollout, in the UK or elsewhere, is given in the available material.^[1]